Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Guus Westra"'
Autor:
Zinia J. Kwidama, Arjo R. Rutten, Gert J.L. Kaspers, Jacqueline Cloos, Gert J. Ossenkoppele, Guus Westra, Bijan Moshaver, Sonja Zweegman, Angèle Kelder, Rolf Wouters, Gerrit Jan Schuurhuis
Publikováno v:
Leukemia Research, 81, 27-34. Elsevier Limited
Moshaver, B, Wouters, R F, Kelder, A, Ossenkoppele, G J, Westra, G A H, Kwidama, Z, Rutten, A R, Kaspers, G J L, Zweegman, S, Cloos, J & Schuurhuis, G J 2019, ' Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia ', Leukemia Research, vol. 81, pp. 27-34 . https://doi.org/10.1016/j.leukres.2019.04.004
Moshaver, B, Wouters, R F, Kelder, A, Ossenkoppele, G J, Westra, G A H, Kwidama, Z, Rutten, A R, Kaspers, G J L, Zweegman, S, Cloos, J & Schuurhuis, G J 2019, ' Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia ', Leukemia Research, vol. 81, pp. 27-34 . https://doi.org/10.1016/j.leukres.2019.04.004
Leukemic stem cells (LSCs), defined by CD34/CD38 expression, are believed to be essential for leukemia initiation and therapy resistance in acute myeloid leukemia. In addition, the side population (SP), characterized by high Hoechst 33342 efflux, ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c670abc779baaf92e630cbde304da081
https://research.vumc.nl/en/publications/ca980246-4a24-4904-b4aa-53285db29f62
https://research.vumc.nl/en/publications/ca980246-4a24-4904-b4aa-53285db29f62
Autor:
Andre P. Abbes, Theresia M. Westers, Arjan A. van de Loosdrecht, Annuska Strunk, Guus Westra, Martine E.D. Chamuleau, Pino J. Poddighe, Tom G. H. Wiggers, Ellen Kuiper-Kramer
Publikováno v:
Cytometry Part B: Clinical Cytometry. 86:280-287
The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in ro
Autor:
N. Feller, Gerrit Jan Schuurhuis, Guus Westra, Geert Weijers, Marjolein A. van der Pol, Taco Waaijman, Gert J. Ossenkoppele
Publikováno v:
Clinical Cancer Research, 11(13), 4793-4801. American Association for Cancer Research Inc.
Feller, N, van der Pol, M A, Waaijman, T, Weijers, G W D, Westra, G, Ossenkoppele, G J & Schuurhuis, G J 2005, ' Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients ', Clinical Cancer Research, vol. 11, no. 13, pp. 4793-4801 . https://doi.org/10.1158/1078-0432.CCR-05-0031
Feller, N, van der Pol, M A, Waaijman, T, Weijers, G W D, Westra, G, Ossenkoppele, G J & Schuurhuis, G J 2005, ' Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients ', Clinical Cancer Research, vol. 11, no. 13, pp. 4793-4801 . https://doi.org/10.1158/1078-0432.CCR-05-0031
Purpose: Several studies have shown survival benefit by autologous stem cell transplantation in acute myeloid leukemia (AML) after purging of grafts. This has, however, not been confirmed in randomized studies due to high toxicity of purging modaliti
Autor:
Peter C. Huijgens, M A van der Pol, Nicole Feller, A van Stijn, Gert J. Ossenkoppele, Gerrit-Jan Schuurhuis, G W D Weijers, Guus Westra
Publikováno v:
Leukemia. 17:68-75
In this study, a high CD34% in autologous peripheral blood stem cell (PBSC) products from 71 AML patients was associated directly with a high relapse rate (P = 0.006) and inversely with disease-free survival (P = 0.003), irrespective whether patients
Autor:
Angelika M. Dräger, Peter C. Huijgens, Gerrit Jan Schuurhuis, Floortje L. Kessler, Elsken van der Wall, Fransien de Boer, Guus Westra, Herbert M. Pinedo, Tanja Netelenbos, Geert Weijers, M. Monnee-Van Muijen, J. W. Oberink
Publikováno v:
Journal of hematotherapy & stem cell research, 11(6), 951. Mary Ann Liebert
Quality assessment of stem cell grafts is usually performed by flow cytometric CD34(+) enumeration or assessment of clonogenic output of fresh material. Previously, we identified the occurrence of early apoptosis, not detectable with the permeability
Autor:
Tom G H, Wiggers, Guus, Westra, Theresia M, Westers, Andre P, Abbes, Annuska, Strunk, Ellen, Kuiper-Kramer, Pino, Poddighe, Arjan A, van de Loosdrecht, Martine E D, Chamuleau
Publikováno v:
Cytometry. Part B, Clinical cytometry.
The strongest prognostic factor in chronic B-cell lymphocytic leukaemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in r
Autor:
Rik A. Brooimans, Nicole Feller, Jan-Willem Gratama, H Wind, I. de Greef, Gerrit-Jan Schuurhuis, V H J van der Velden, Patrik Aerts, Angèle Kelder, Nancy Boeckx, M. Leenders, J. G te Marvelde, Frank Preijers, Guus Westra
Publikováno v:
Blood Cancer Journal, 3, pp. e129
Blood Cancer Journal
Feller, N, van der Velden, V H J, Brooimans, R A, Boeckx, N, Preijers, F, Kelder, A, de Greef, I, Westra, G, te Marvelde, J G, Aerts, P, Wind, H, Leenders, M, Gratama, J W & Schuurhuis, G J 2013, ' Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting ', Blood cancer journal, vol. 3, e129 . https://doi.org/10.1038/bcj.2013.27
Blood Cancer Journal, 3, e129
Blood cancer journal, 3:e129. Nature Publishing Group
Blood Cancer Journal, 3. Nature Publishing Group
Blood Cancer Journal
Feller, N, van der Velden, V H J, Brooimans, R A, Boeckx, N, Preijers, F, Kelder, A, de Greef, I, Westra, G, te Marvelde, J G, Aerts, P, Wind, H, Leenders, M, Gratama, J W & Schuurhuis, G J 2013, ' Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting ', Blood cancer journal, vol. 3, e129 . https://doi.org/10.1038/bcj.2013.27
Blood Cancer Journal, 3, e129
Blood cancer journal, 3:e129. Nature Publishing Group
Blood Cancer Journal, 3. Nature Publishing Group
Contains fulltext : 186455.pdf (Publisher’s version ) (Open Access) Flow-cytometric detection of minimal residual disease (MRD) has proven in several single-institute studies to have an independent prognostic impact. We studied whether this relativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f88cada1faa950de5a787ab4c72389e
https://hdl.handle.net/2066/186455
https://hdl.handle.net/2066/186455
Autor:
Anjo J.P. Veerman, Guus Westra, Rob Pieters, Gert J. Ossenkoppele, E. Klumper, D. R. Huismans, A. H. Loonen, Antoinette Rottier
Publikováno v:
British Journal of Haematology. 93:903-910
The efficacy of chemotherapy in acute myeloid leukaemia (AML) is limited by clinical drug resistance. We determined in vitro resistance to cytosine arabinoside (ARAC), daunorubicin (DNR), mitoxantrone (MITOX), m-amsacrine (AMSA) and etoposide (VP16)
Autor:
Eddy, Supriyadi, Pudjo H, Widjajanto, Anjo J p, Veerman, Ignatius, Purwanto, Yetty M, Nency, Stefanus, Gunawan, Selvi, Nafianti, Dewajani, Purnomosari, Umi S, Intansari, Guus, Westra, Jacqueline, Cloos
Publikováno v:
Asian Pacific journal of cancer prevention : APJCP. 12(12)
Immunophenotyping, as suggested by WHO, may improve diagnosis of childhood leukemia since it offers a better classification of the hematopoietic lineage of malignant cells as compared to morphology. Therefore, we aimed to determine the proportion of
Publikováno v:
Feller, N, Kelder, A, Westra, G A, Ossenkoppele, G J & Schuurhuis, G J 2008, ' Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants ', Cytometry Part B. Clinical Cytometry, vol. 74, no. 1, pp. 9-16 . https://doi.org/10.1002/cyto.b.20375
Cytometry Part B. Clinical Cytometry, 74(1), 9-16. Wiley-Liss Inc.
Cytometry Part B. Clinical Cytometry, 74(1), 9-16. Wiley-Liss Inc.
Background: Several studies showed the benefit of purging of acute myeloid leukemia (AML) stem cell transplants. We reported previously that purging by positive selection of CD34+ and CD133+ cells resulted in a 3–4 log tumor cell reduction (TCR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65566679db28a6bbef5e93fbf4ddb981
https://research.vumc.nl/en/publications/f069f885-bd75-4e21-9302-8ae10a287275
https://research.vumc.nl/en/publications/f069f885-bd75-4e21-9302-8ae10a287275